Name

Metabolic Solutions Development

Legal name

Metabolic Solutions Development Company

Website

https://msdrx.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Therapeutics

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Drug discovery therapeutics
• Metabolic disease treatment
• Insulin sensitizer development
• NASH clinical development
• Mitochondrial drug research

Headquarters

HQ city

Kalamazoo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Licensing/Development Deals: Pre-revenue drug development company pursuing licensing agreements and strategic partnerships with larger pharmaceutical companies for clinical development and commercialization of its novel therapeutics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Metabolic Solutions Development Company (MSDC) is a drug discovery and development company that creates novel pharmaceutical therapeutics based on its proprietary mTOT (mitochondrial Target of Thiazolidinediones) Modulator platform. The company's two lead clinical-stage compounds — MSDC-0160 (targeting type 2 diabetes, Alzheimer's and Parkinson's disease) and MSDC-0602K (targeting NASH, advanced through spin-off Cirius Therapeutics) — selectively modulate mitochondrial proteins to improve insulin sensitivity without the dose-limiting side effects of traditional insulin sensitizers.

Product overview

Metabolic Solutions Development Company (MSDC) is a drug discovery and development company with a focused pipeline of two novel mTOT Modulators: MSDC-0160, being developed for neurodegenerative diseases (Alzheimer's and Parkinson's) and type 2 diabetes, and MSDC-0602 (now advanced through Cirius Therapeutics), in Phase 2 trials for NASH. Both compounds work through mTOT (mitochondrial Target of Thiazolidinediones), a novel protein complex in the inner mitochondrial membrane that serves as the mechanism of action for insulin sensitization.

Differentiator

Problem solved

Functional benefit

Brands

• mTOT Modulators: A new class of insulin sensitizing compounds developed by MSDC that selectively bind and modulate proteins in the mTOT (mitochondrial Target of Thiazolidinediones) complex.
• EMMINENCE Trial

Products and services

• MSDC-0160

Quantifiable outcome

• Phase 2b study met primary endpoint of significantly reducing fasting plasma glucose (FPG) in type 2 diabetes patients
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and major.

• Cirius Therapeutics (formerly Octeta Therapeutics)coreStrategic or Co-development Partner · 11 April 2017Octeta Therapeutics (later renamed Cirius Therapeutics) was formed by MSDC in June 2016 to advance the clinical development of MSDC-0602K, currently in Phase 2 clinical trial (EMMINENCE Trial) for NASH treatment. In April 2017, Cirius completed $40 Million Series A financing led by Frazier Healthcare Partners and Novo A/S to fund the Phase 2b study.
• Rush University Medical CentermajorStrategic or Co-development PartnerClinical research partner conducting Phase 2a study of MSDC-0160 in patients diagnosed with mild to moderate Alzheimer's disease dementia.
• Van Andel InstitutemajorStrategic or Co-development PartnerResearch collaboration with Patrik Brundin, MD, PhD and his Laboratory for Translational Parkinson's Disease Research to study neuroprotective effects of MSDC-0160 in Parkinson's disease models.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Cirius Therapeutics: Cirius was originally formed as a spin-off of MSDC (formerly Octeta Therapeutics) to advance MSDC-0602K for NASH. As the vehicle carrying forward MSDC's most clinically advanced asset, it is the single most directly comparable peer and is built on the same mTOT technology platform.
• Madrigal Pharmaceuticals: Clinical-stage biopharmaceutical company developing resmetirom (Rezdiffra), the first FDA-approved treatment for NASH. Comparable to MSDC as a metabolic disease-focused company with small molecule therapeutics targeting the same patient population MSDC-0602K addresses.
• Intercept Pharmaceuticals: Specialty pharmaceutical company developing obeticholic acid for NASH and other liver diseases. Directly comparable to MSDC's NASH program (MSDC-0602K) as a competitor pursuing novel small molecule therapies for nonalcoholic steatohepatitis.
• Genfit: French biopharmaceutical company developing elafibranor for NASH and other metabolic disorders. Comparable to MSDC's NASH program as a focused small-molecule developer targeting the same disease.
• Viking Therapeutics: Clinical-stage biopharmaceutical company developing novel small molecule therapeutics for metabolic and endocrine disorders, including NASH (VK2809) and obesity. Directly comparable to MSDC's pipeline of insulin sensitizers for metabolic disease.
• Poxel: French biopharmaceutical company developing Imeglimin, an oral T2D therapy with a novel mechanism targeting mitochondrial dysfunction. Highly comparable to MSDC's mTOT approach as both target mitochondrial mechanisms of insulin sensitization.
• vTv Therapeutics: Clinical-stage pharmaceutical company developing cadisegliatin, an oral adjunctive therapy for type 2 diabetes. Comparable to MSDC as a small-cap clinical-stage developer of novel oral therapies for metabolic disease with similar insulin sensitization focus.
• Anavex Life Sciences: Clinical-stage biopharmaceutical company developing small molecule therapeutics (e.g., blarcamesine) for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Directly comparable to MSDC-0160's CNS indications.
• Cassava Sciences: Clinical-stage biotechnology company developing simufilam for Alzheimer's disease. Comparable to MSDC as a small-cap clinical-stage developer pursuing novel CNS mechanisms for Alzheimer's.

Emerging players

• INmune Bio: Clinical-stage biotechnology company developing therapies that target the innate immune system for Alzheimer's disease and other neurodegenerative conditions. Comparable to MSDC's CNS pipeline as a smaller, focused neurodegenerative disease developer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/msdrx
• LinkedInlinkedin.com/company/metabolic-solutions-development-company

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Metabolic Solutions Development